» Articles » PMID: 22159600

Profilin 1 is a Potential Biomarker for Bladder Cancer Aggressiveness

Abstract

Of the most important clinical needs for bladder cancer (BC) management is the identification of biomarkers for disease aggressiveness. Urine is a "gold mine" for biomarker discovery, nevertheless, with multiple proteins being in low amounts, urine proteomics becomes challenging. In the present study we applied a fractionation strategy of urinary proteins based on the use of immobilized metal affinity chromatography for the discovery of biomarkers for aggressive BC. Urine samples from patients with non invasive (two pools) and invasive (two pools) BC were subjected to immobilized metal affinity chromatography fractionation and eluted proteins analyzed by 1D-SDS-PAGE, band excision and liquid chromatography tandem MS. Among the identified proteins, multiple corresponded to proteins with affinity for metals and/or reported to be phosphorylated and included proteins with demonstrated association with BC such as MMP9, fibrinogen forms, and clusterin. In agreement to the immobilized metal affinity chromatography results, aminopeptidase N, profilin 1, and myeloblastin were further found to be differentially expressed in urine from patients with invasive compared with non invasive BC and benign controls, by Western blot or Elisa analysis, nevertheless exhibiting high interindividual variability. By tissue microarray analysis, profilin 1 was found to have a marked decrease of expression in the epithelial cells of the invasive (T2+) versus high risk non invasive (T1G3) tumors with occasional expression in stroma; importantly, this pattern strongly correlated with poor prognosis and increased mortality. The functional relevance of profilin 1 was investigated in the T24 BC cells where blockage of the protein by the use of antibodies resulted in decreased cell motility with concomitant decrease in actin polymerization. Collectively, our study involves the application of a fractionation method of urinary proteins and as one main result of this analysis reveals the association of profilin 1 with BC paving the way for its further investigation in BC stratification.

Citing Articles

Recent progress in mass spectrometry-based urinary proteomics.

Joshi N, Garapati K, Ghose V, Kandasamy R, Pandey A Clin Proteomics. 2024; 21(1):14.

PMID: 38389064 PMC: 10885485. DOI: 10.1186/s12014-024-09462-z.


Dipeptidyl peptidase 1 inhibition as a potential therapeutic approach in neutrophil-mediated inflammatory disease.

Chalmers J, Kettritz R, Korkmaz B Front Immunol. 2024; 14:1239151.

PMID: 38162644 PMC: 10755895. DOI: 10.3389/fimmu.2023.1239151.


Association of PFN1 Gene Polymorphisms with Bone Mineral Density, Bone Turnover Markers, and Osteoporotic Fractures in Chinese Population.

Wu Y, Wu S, Yang E, Zhang G, Shi Q, Liang J Calcif Tissue Int. 2023; 113(2):207-215.

PMID: 37401976 DOI: 10.1007/s00223-023-01102-2.


A simple urine test by 3D-plus-3D immunoassay guides precise cancer diagnosis.

Kim H, Moon O, Seol Y, Lee J Bioeng Transl Med. 2023; 8(3):e10489.

PMID: 37206218 PMC: 10189436. DOI: 10.1002/btm2.10489.


Comprehensive proteomics and platform validation of urinary biomarkers for bladder cancer diagnosis and staging.

Vanarsa K, Castillo J, Wang L, Lee K, Pedroza C, Lotan Y BMC Med. 2023; 21(1):133.

PMID: 37016361 PMC: 10074794. DOI: 10.1186/s12916-023-02813-x.


References
1.
Bae Y, Ding Z, Zou L, Wells A, Gertler F, Roy P . Loss of profilin-1 expression enhances breast cancer cell motility by Ena/VASP proteins. J Cell Physiol. 2008; 219(2):354-64. PMC: 2990882. DOI: 10.1002/jcp.21677. View

2.
Wittenmayer N, Jandrig B, Rothkegel M, Schluter K, Arnold W, Haensch W . Tumor suppressor activity of profilin requires a functional actin binding site. Mol Biol Cell. 2004; 15(4):1600-8. PMC: 379259. DOI: 10.1091/mbc.e03-12-0873. View

3.
Makridakis M, Gagos S, Petrolekas A, Roubelakis M, Bitsika V, Stravodimos K . Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancer. Proteomics. 2008; 9(2):287-98. DOI: 10.1002/pmic.200800121. View

4.
de Seny D, Fillet M, Ribbens C, Maree R, Meuwis M, Lutteri L . Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis. Clin Chem. 2008; 54(6):1066-75. DOI: 10.1373/clinchem.2007.099549. View

5.
Konety B . Molecular markers in bladder cancer: a critical appraisal. Urol Oncol. 2006; 24(4):326-37. DOI: 10.1016/j.urolonc.2005.11.023. View